Enlivex Ltd.(ENLV)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 6 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ENLV Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Enlivex Ltd. (ENLV), a Healthcare sector company. ENLV is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 6 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2025), Enlivex Ltd. reports net income of $1.2B, free cash flow of $-10.5M. Top institutional holders of ENLV by reported 13-F value include GOLDMAN SACHS GROUP, GROUP ONE TRADING, L.P., WELLS FARGO & COMPANY/MN, based on the most recent SEC filings. ENLV trades on the Nasdaq exchange and files with the SEC under CIK 1596812. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENLV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Enlivex Ltd. directly from SEC EDGAR.
Net Income
FY 2025
$1.2B
Free Cash Flow
FY 2025
$-10.5M
Get alerted when ENLV's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Enlivex Ltd. including:
Top Institutional Holders of ENLV
GOLDMAN SACHS GROUP INC
$23.4K13,935 shGROUP ONE TRADING, L.P.
$20.3K12,100 shWELLS FARGO & COMPANY/MN
$15.4K9,184 shMORGAN STANLEY
$1.6K954 shBANK OF AMERICA CORP /DE/
$244.00145 shPROEQUITIES, INC.
$0.000 sh
| Fund | Value | Shares |
|---|---|---|
| GOLDMAN SACHS GROUP INC | $23.4K | 13,935 |
| GROUP ONE TRADING, L.P. | $20.3K | 12,100 |
| WELLS FARGO & COMPANY/MN | $15.4K | 9,184 |
| MORGAN STANLEY | $1.6K | 954 |
| BANK OF AMERICA CORP /DE/ | $244.00 | 145 |
| PROEQUITIES, INC. | $0.00 | 0 |
More Healthcare Companies
View all Healthcare →Put ENLV on your watchlist
Track score changes the day Enlivex Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ENLV a good stock to buy?
13F Pro's AI-powered analysis of Enlivex Ltd. (ENLV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENLV are available on the ENLV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ENLV?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENLV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Enlivex Ltd.'s investment landscape.